Biochip engagement expands to include foundry in Spain

In this edition of Archer’s Newsletter we highlight the Company’s progress in the foundry fabrication of its Biochip devices and provide greater context to the graphene field effect transistors (gFETs) at the core of this technology.

Archer is currently developing various gFET designs through the engagement of commercial semiconductor foundries in Europe. This has the potential to increase the applications of Archer’s Biochip, improve quality control, and bolster future semiconductor supply chain resilience.

Performing wafer runs in several foundries is required as part of Archer’s gFET chip development process to optimise device designs and manufacturing for foundry readiness and compatibility.

Archer sent a new Biochip gFET design to a foundry partner in Spain for fabrication through a four-inch whole wafer run. The gFETs are designed with structures suitable for liquid multiplexing, with advances over previous chip features including gating and channel definition.

Delivery of the new gFETs is expected in the first half of 2024 for testing in Archer’s Australian laboratories, and I look forward to updating you on the outcomes of this work.

Sincerely,

Dr Mohammad Choucair, FRACI FRSN GAICD
Chief Executive Officer
Archer Materials Limited (ASX: AXE)

Click here to view the full Newsletter